Genentech at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Genentech brings 6 presentations to ASH 2026 in New Orleans, and exhibits at Booth 439. Genentech presents a theater session on long-term follow-up of the POLARIX lymphoma study and hosts a hemophilia A and von Willebrand disease trial showcase. It also supports symposia on bispecifics and ADCs.
| Organization | ASH 2026 Attendance |
|---|---|
Genentech South San Francisco, CA | |
Biotechnology company and member of the Roche Group, with medicines for blood cancers and hemophilia. | Booth Exhibiting at Booth 439 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Talk Fri Dec 11 4:00pm–4:50pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma. Talk Sat Dec 12 1:30pm–1:45pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Talk Mon Dec 14 8:00am–9:00am |
Find decision makers at Genentech
Tell us what you sell and we’ll find the people at Genentech most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction